
zzso zzso of human breast zzso zzso the zzso zzso zzso which zzso a more aggressive tumor zzso and associates with a poor prognosis in patients with this zzso Two approved therapies targeting zzso the zzso zzso zzso and the zzso zzso inhibitor zzso are clinically active against this type of breast zzso However, a significant fraction of patients with zzso breast cancer treated with these agents eventually zzso or develop progressive zzso This suggests that tumors acquire or possess intrinsic mechanisms of resistance that allow escape from zzso zzso This review focuses on mechanisms of intrinsic and/or acquired resistance to zzso therapies that have been identified in zzso and clinical zzso These mechanisms involve zzso to zzso itself, zzso or acquisition of bypass signaling through other zzso or zzso signaling zzso defects in mechanisms of cell cycle regulation or zzso and host factors that may zzso drug zzso Emerging clinical evidence already suggests that combinations of therapies targeting zzso as well as these resistance pathways will be effective in overcoming or preventing zzso 

